Gencaro bucindolol: Additional Phase III data

Additional data from the double-blind, North American Phase III BEST trial in 2,708 patients showed that Gencaro reduced the risk of new-onset atrial fibrillation (AF) by 41% vs. placebo. Additionally, a genetic sub-study of 1,040 patients with homozygous arginine at the amino acid position 389 beta-1 adrenergic receptor polymorphism showed that Gencaro significantly reduced the risk of new-onset AF by 74% vs. placebo (p=0.0005). Arca previously said the genotype is the most favorable for treatment with Gencaro. Data were presented at the American Heart Association meeting in Orlando. Arca previously reported that Gencaro missed the primary endpoint of significantly reducing mortality vs. placebo (see BioCentury, April 6, 2009 & Jan. 25, 2010). ...